Fontolizumab

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.[3]

Fontolizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetinterferon gamma
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Molar massca. 150 kg/mol
 NY (what is this?)  (verify)

References
  1. Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
  2. Reinisch, W; De Villiers, W; Bene, L; Simon, L; Rácz, I; Katz, S; Altorjay, I; Feagan, B; et al. (2009). "Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory Bowel Diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334.
  3. Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.